AI arkistot | MVision AI

The Current State of Cancer Care and Radiotherapy in the US

Cancer care and radiotherapy in the US continue to face sustained demand as cancer incidence remains high across the population. According to the American Cancer…

Refining Volumes – a Study on Cardiac Substructures’ Impact on Survival in Lung Cancer Patients Treated with Radiation Therapy

Cardiac diseases and cancers are leading causes of death [1]. Many cancer patients have preexistent cardiac impairment or have risk factors of developing it. On…

Time Optimisation in Radiation Therapy Planning: Insights from UK Surveys

Recently published data give a glimpse on the time spent for treatment preparation in UK radiation oncology centres. As expected,organ-at-risk and target contouring contouring is…

MVision AI receives TGA approval and market authorization for Australia

HELSINKI, Finland – May 1, 2024 An application for MVision AI Segmentation (Contour+) has been submitted and accepted by the Therapeutic Goods Administration (TGA) under…

MVision AI is delighted to announce that we have received our 2nd order for the Republic of Ireland from St. Luke’s Radiation Oncology Network (SLRON)

Finland, Helsinki, February 19, 2024 The contract for installing Contour+ Guideline Based AI Segmentation tool has been won through the public tender process and implies…

World Cancer Day – Joining efforts for a better cancer care

World cancer day, celebrated on the 4th of February, was established more than 20 years ago. It represents an initiative of the Union for International…

MVision AI Announces Partnership with Medron Medical Systems (Canada)

HELSINKI, Finland – January 22, 2024 MVision AI, a premier software service provider of GBS™ (Guideline-Based Segmentation) solution for same-day radiotherapy treatment planning, proudly announces…

The world’s first comprehensive GBS™ solution for radiation therapy cancer treatment is now available for implementation in Canadian clinics

HELSINKI, Finland – January 22, 2024 MVision AI announces first Health Canada Medical Device License for MVision AI Segmentation (Contour+). In conjunction with Guide and…